In this blog post, we’ll dive into the latest earnings reports from ELV, TMO, and DHR, three healthcare companies that have seen significant growth in their respective segments. We’ll explore the key takeaways from each company’s 3Q earnings report and what they mean for investors.

ELV:
ELV reported 3Q26 adjusted EPS of $6.99, beating GS/Visible Alpha Consensus Data of $4.99/$4.68 by 40%/49%. The favorable MLR across government-subsidized lines of business (60-bps better vs consensus) and stronger Carelon profitability drove the impressive earnings beat. ELV also raised its 2026 adjusted EPS guidance to at least $29.00, versus at least $27.00 previously and GS/consensus of $27.05/$23.78. This indicates a significant increase in the company’s growth potential.

TMO:
TMO’s 3Q revenue growth was slightly ahead of consensus, with organic revenue growth of +6% vs +4.3% consensus. While life sci was slightly below estimates, products and services revenue came in above expectations. The company’s adjusted operating margin was 24.5%, slightly higher than the estimated 24.0%. Management will provide a guide for the upcoming call, but no details were provided.

DHR:
DHR reported mixed 3Q earnings, with biotech and instruments segments performing well. Biotech segment grew +5% organically with BPS upper end of +MSD (slightly better than expectations), while reported revenue was light of consensus. The company also guided for core revenue growth excl respiratory +4% to +5%, with total DHR growth of +3%. EPS guide was increased to $8.57 to $8.62, driven by lower respiratory expectations.

Overall, these earnings reports suggest a positive outlook for the healthcare industry. Favorable MLR and product growth are driving success for these companies, and their guidance for future growth is promising. As always, it’s important to do your own research and consult with a financial advisor before making any investment decisions.